Objectives: Recent evidence suggests that half-dose thrombolysis for pulmonary embolism may provide similar efficacy with reduced bleeding risk compared with full-dose therapy, but comparative studies are lacking. We aimed to evaluate the effectiveness and safety of half-dose versus full-dose alteplase for treatment of pulmonary embolism. Design: A retrospective cohort study comparing outcomes in patients receiving half-dose (50 mg) versus full-dose (100 mg) alteplase for pulmonary embolism. We used propensity score matching and sensitivity analyses to address confounding and hospital-level clustering. Setting: Data from 420 hospitals obtained from the Premier Healthcare Database between January 2010 and December 2014. Subjects: Adult critically ill patients with acute pulmonary embolism treated with IV alteplase therapy.
thrombolytic therapy in patients with intermediate-risk PE is controversial due to less clear delineation between benefits and risks (3, (10) (11) (12) (13) (14) . The majority of evidence supporting use of thrombolytic therapy for intermediate-risk PE focuses on minimizing treatment escalation, and expediting return to normal functional status with reduced risk of pulmonary hypertension, rather than demonstrating reduced mortality (3, 6, 11, 12) . These less definitive clinical benefits of thrombolytic therapy in this setting are tempered by the risk of cerebral hemorrhage and major bleeding, which may be as high as 2% and 6%, respectively (11) . Given the potential for bleeding and the premise that the pulmonary vasculature receives the majority of any intravenously administered thrombolytic dose, it has been suggested that lower dose thrombolytics may provide sufficient efficacy while reducing the risk of major bleeding (6, (15) (16) (17) (18) . This hypothesis is supported by recent evidence suggesting that using half the usual dose of alteplase in the setting of PE may be effective with a reduced bleeding risk (6, 16, 17) . However, there is currently limited evidence comparing treatment outcomes between full-dose and low-dose thrombolytic strategies for managing patients with acute PE.
We conducted a multicenter pharmacoepidemiologic study to compare the effectiveness of half-dose versus full-dose alteplase for the treatment of patients with acute PE admitted to the ICU. Our primary outcome was to assess the need for treatment escalation between groups. Additionally, we aimed to determine differences in safety, important clinical outcomes, and cost. We hypothesized that half-dose alteplase would be associated with similar effectiveness compared with full-dose alteplase with a reduced risk of major bleeding.
METHODS

Study Design
This was an observational cohort study evaluating patient data voluntarily submitted to the Premier Incorporated's Perspective database over a 5-year period. The database includes information from over 700 U.S. hospitals with comprehensive billing, cost, device, medication, and procedure data (19, 20) . The study was approved by the Colorado Multiple Institutional Review Board.
Patient Population
Patients greater than or equal to 18 years old were included if they were admitted to the ICU on hospital day 1 or 2 between January 1, 2010, and December 31, 2014, with a primary diagnosis of PE (International Classification of Diseases, 9th Edition [ICD-9] code 415.1), and treated with alteplase 50 or 100 mg IV as the initial thrombolytic strategy. Patient's receiving alteplase doses other than 50 or 100 mg and those receiving catheter thrombus fragmentation as their first intervention for PE were not included. Patients were categorized into either half-dose (alteplase 50 mg IV) or full-dose (alteplase 100 mg IV) treatment groups based upon the first dose of alteplase administered.
Outcomes
The primary outcome evaluated in this study was treatment escalation, defined as initiation of vasopressors, need for secondary thrombolysis, assisted ventilation, embolectomy, catheter thrombus fragmentation, inferior vena cava filter placement, or cardiopulmonary resuscitation occurring after first alteplase administration (3). Secondary effectiveness outcomes included hospital mortality, readmission for PE, ICU length of stay, hospital length of stay, and total hospital charges. Safety outcomes were major bleeding (defined as a documented cerebral hemorrhage, gastrointestinal bleeding, acute blood loss anemia, administration of packed RBCs, or administration of aminocaproic acid, tranexamic acid, or factor VIIa after alteplase administration) and documentation of a fibrinolytic therapy-related adverse event. Occurrence of an outcome was determined via pharmacy charge codes, current procedural terminology codes, or ICD-9 codes as appropriate (Appendix A, Supplemental Digital Content 1, http://links. lww.com/CCM/D667).
Data Analysis
Statistical analysis was performed (by author R.R.A.) using methodology previously described by the Colorado Pulmonary Outcomes Research Group with minor modifications (21) . Patient and hospital characteristics were compared between groups using the chi-square test of Fisher exact test for categorical data and the unpaired t test or Kruskal-Wallis test for continuous variables as appropriate. Description of propensity score matching and additional information relating to statistical methods, bias mitigation, and results validation via internal data are detailed in Appendix A (Supplemental Digital Content 1, http://links.lww.com/CCM/D667) (22) .
The propensity score matched analysis adjusted for unbalanced covariates was the principal analysis for interpretation of study outcomes. Using a 1:1 matched design and a treatment escalation rate of 41%, this study had more than 90% power to detect an absolute difference of 10% in the need for treatment escalation. All significance tests were two-sided, and a p value less than 0.05 was considered significant. All analyses were conducted using SAS version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
A total of 3,768 patients from 420 hospitals were included in the analysis, 3,069 (81.4%) in the full-dose group and 699 (18.6%) in the half-dose group (eFig. 1, Supplemental Digital Content 2, http://links.lww.com/CCM/D668). Half-dose alteplase use increased from 16% of patients in 2010 to 20% of patients in 2014 (p = 0.05). Overall, most patients were less than 65 years old, 50% were male, 69% were Caucasian, and the predominant comorbidities were venous thromboembolism, hypertension, obesity, diabetes, cardiac arrhythmias, and fluid and electrolyte disorders ( Table 1 ; and eTable 1, Supplemental Digital Content 3, http://links.lww.com/CCM/D669). Patients were most commonly admitted to urban hospitals with greater than 500 beds located in the southern region of the United States. Approximately 44% of patients were treated at teaching institutions. Within 24 hours before alteplase administration, 36% were receiving vasopressor therapy, 26% invasive mechanical ventilation, and 11% noninvasive ventilation ( Table 2) . The majority of patients received alteplase therapy on hospital day 1 (median, hospital day 1; interquartile range [IQR], 1-2 d). Patients receiving full-dose alteplase therapy had a similar number of elderly patients (> 65 or > 75 yr old) ( Table 1 ) but had more comorbidities (e.g., hypertension, diabetes, heart failure, and pulmonary circulation disease) compared with patients in the half-dose alteplase group. Patients receiving full-dose alteplase were more likely to have a high-risk PE as indicated by increased use of vasopressor therapy, and had higher rates of mechanical ventilation and tests drawn to measure cardiac function ( Table 2 ). The majority of patients received unfractionated heparin in addition to thrombolytic therapy; however, some transition between unfractionated heparin and low molecular weight heparin occurred. The median (IQR) total alteplase dose administered during hospitalization was 100 mg (100-100 mg) in the fulldose group and 50 mg (50-100 mg) in the half-dose group. In the patients (n = 341) who received a second alteplase dose, the median time to the second dose was one hospital day (IQR, 1-1). The time to secondary thrombolysis was not different between treatment groups (p = 0.67). In-hospital mortality was 21% in the full-dose group compared with 12% in the half-dose group (p < 0.01). The median hospital length of stay was shorter in the full-dose group (6 d; IQR, 4-10 d) compared with the half-dose group (7 d; IQR, 4-12 d) (p < 0.01).
Propensity-Matched Analysis (Primary Analysis)
After propensity matching, 78% of patients in the half-dose group (n = 548) were matched 1:1 with an equal number of patients in the full-dose group. Propensity matching successfully eliminated discordance among patient characteristics (eTable 2, Supplemental Digital Content 4, http://links.lww. com/CCM/D670) and hospital characteristics, early therapies, and tests (eTable 3, Supplemental Digital Content 5, http:// links.lww.com/CCM/D671).
The prespecified primary outcome of treatment escalation occurred more frequently in patients receiving half-dose (54%) compared with full-dose alteplase (41%) (p < 0.01) (Tables 3 and 4). Increased treatment escalation in the half-dose group was driven by greater need for additional thrombolysis and higher utilization of thrombosis fragmentation by catheter (p < 0.01 for both). There were no differences in the need for vasopressor therapy, assisted ventilation, embolectomy, cardiopulmonary resuscitation, or inferior vena cava (IVC) filter placement (p > 0.05 for all). Half-dose alteplase was associated with increased hospital charges of approximately $23,000 per patient ( Table 4) . Cerebral hemorrhage occurred in 0.5% and 0.4% of patients in the half-dose and full-dose groups, respectively ( Table 5) . No differences in any type of major bleeding, need for reversal agents, or documented fibrinolytic related adverse events were observed.
Multivariate Analyses of the Entire Study Cohort
The total cohort (i.e., 3,768 patients) was analyzed after adjusting for the propensity to be treated with half-dose alteplase and differences in patient characteristics, admission year, comorbidities, hospital characteristics, early therapies, and tests. Similar to the propensity-matched analysis, this multivariate analysis showed that patients receiving full-dose therapy were less likely to require treatment escalation and was associated with a reduction in total hospitalization charges (Table 5) . Conditional regression evaluating patient age, obesity, hypertension, renal failure, hepatic disease, anticoagulant use, and coagulopathy demonstrated similar results.
Subgroup Analyses of Intermediate-Risk PE Patients
Primary and secondary outcome measures were evaluated in the intermediate-risk PE subgroup of patients by removing patients requiring vasopressor therapy and performing propensity matching among these patients. Patient and hospital characteristics are presented in eTable 4 (Supplemental Digital Content 6, http://links.lww.com/CCM/D672) and eTable 5 (Supplemental Digital Content 7, http://links.lww.com/CCM/D673). In the propensity score-matched analysis, treatment escalation was observed in 46% of the half-dose compared with 31% of the fulldose treated patients (p < 0.01). Hospital mortality rate was 5% in the half-dose group compared with 7% in the full-dose group (p = 0.15). Outcomes for the entire cohort and the propensitymatched cohort are presented in eTable 6 (Supplemental Digital Content 8, http://links.lww.com/CCM/D674). Similar to the entire cohort, treatment with half-dose alteplase for intermediate-risk PE was associated with more treatment escalation and an increased hospital charges, compared with full-dose alteplase. There were no differences in bleeding or documented fibrinolytic adverse effects between treatment groups.
Subgroup Analyses of High-Risk PE Patients
Evaluation of high-risk PE patients was completed using a propensity-matched model including only patients requiring vasopressor therapy at the time of alteplase administration. Patient and hospital characteristics are listed in eTable 7 (Supplemental Digital Content 9, http://links.lww.com/ CCM/D675) and eTable 8 (Supplemental Digital Content 10, http://links.lww.com/CCM/D676). In the propensity-matched model, treatment escalation occurred in 83.1% of patients in each group (p = 0.99). Vasopressor usage was still required in 62% of half-dose patients and in 65% of full-dose patients the day after thrombolysis (p = 0.59). A second dose of alteplase was administered to 18.6% of half-dose patients and 2.5% of full-dose patients (p < 0.01). Hospital mortality was 40.7% in the half-dose group and 45.8% in the full-dose group (p = 0.43). Half-dose alteplase was associated with increased hospital charges, but no differences in clinical outcomes were observed (eTable 9, Supplemental Digital Content 11, http:// links.lww.com/CCM/D677). No differences in bleeding or fibrinolytic adverse effects were observed. 
Subgroup Analyses of Patients Without Escalation of
Sensitivity Analysis of the Entire Cohort
When analyses were reconducted to account for the rate of half-dose alteplase utilization at the hospital where they were admitted, results for hospital mortality were similar (Table 4) . Consistent with the finding that half-dose therapy was associated with increased treatment escalation, for each 10% increase in the proportion of half-dose alteplase used by a hospital, the need for escalation of care is increased (Table 4) . Results for the hierarchical analyses were not different from the propensitymatched and multivariate models.
DISCUSSION
This study demonstrates that half-dose alteplase is used as the initial treatment strategy over full-dose alteplase in approximately 19% of ICU patients with acute PE, and its use appears to be expanding as demonstrated by an increased proportional use from 2010 to 2014. Full-dose alteplase therapy appears favored by clinicians in patients with high-risk PE, with less than a quarter of patients in the half-dose group receiving vasopressors at the time of thrombolysis. Additionally, at the time of alteplase administration, patients treated with half-dose therapy were less likely to be receiving mechanical ventilation and less commonly evaluated via cardiac function tests. After propensity matching, the use of half-dose alteplase was associated with similar rates of in-hospital mortality and major bleeding compared with full-dose alteplase therapy; however, patients receiving half-dose alteplase were more likely to need further escalation in care for the management of their acute PE. The overall observed in-hospital mortality in our study was 20%, which is similar to previous data including high-risk PE patients (23), and highlights the importance of management strategies to improve mortality in acute PE. After propensity score matching, there was no difference in mortality observed between half-dose and full-dose alteplase, suggesting that half-dose therapy produces similar survival rates in acute PE. However, this outcome is driven mostly by the ≈64% of study patients with intermediaterisk PE, where the mortality rate was lower at 5-7%. Studies to date have been unable to elucidate a significant effect of thrombolysis on mortality when compared with placebo in intermediate-risk PE (3, 11) . Similarly, the only study prospectively evaluating half-dose versus full-dose alteplase demonstrated similar mortality rates between treatment groups (2% vs 6%) (17) . Therefore, it is unlikely that any pragmatic study would be able to determine a significant difference on mortality due to alteplase dosing in this population. The infrequent use of half-dose alteplase in patients on vasopressor therapy limits the ability to draw firm conclusions regarding the impact of alteplase dosing on mortality in patients with high-risk PE. Due to the lack of severely ill patients (e.g., vasopressor treated) available for comparison from the half-dose cohort, fewer patients with high-risk PE were available for matching. Given the high rate of mortality in high-risk PE and the lack of conclusive data for halfdose therapy in this population, it seems most prudent to continue to recommend full-dose alteplase therapy in patients with hemodynamic decompensation due to acute PE. Treatment escalation was common in both half-dose and full-dose alteplase treatment groups with more than 40% of patients requiring further advanced interventions to manage their acute PE. The need for treatment escalation is higher than reported in previous studies (10-25%) and likely reflects the inclusion of patients with high-risk PE (e.g., higher rates of vasopressor use) and our addition of inferior vena cava filter placement to the criteria (3). Treatment escalation was more common in patients receiving half-dose alteplase therapy and was driven by the more frequent administration of a second alteplase dose or the use of thrombosis fragmentation by catheter. The lack of differences between treatment groups in the need for vasopressors, assisted ventilation, cardiopulmonary resuscitation, and IVC filter placement after the first dose of alteplase makes it difficult to elucidate whether secondary thrombolysis and thrombosis fragmentation by catheter was preplanned or as a result of patient decompensation. Previous studies have shown comparable improvements in echocardiographic findings or right heart strain and perfusion scans with half-dose versus full-dose alteplase therapy (17, 18) . Half-dose alteplase therapy has also demonstrated effectiveness in reducing pulmonary hypertension acutely after administration (6) . There has been some suggestion that half-dose therapy may be most reasonable in patients with lower body weight (< 65 kg) and those at higher risk of bleeding (17, 24) . In our study, both treatment approaches yielded similar mortality, but escalation of care in the half-dose group was associated with a substantially increased hospital charges (≈$25,000 increase per patient). Half-dose and full-dose alteplase were associated with similar rates of major bleeding. Of the 3,768 patients treated with alteplase therapy, cerebral hemorrhage occurred in 18 patients (0.5%), which is consistent with previous studies of alteplase for acute PE (3, 6, 11) . Documentation of acute blood loss anemia and the administration of packed RBCs or antifibrinolytic agents after alteplase administration was similar between treatment groups. Our findings are contrary to previous studies that suggest that lower doses of alteplase may significantly reduce bleeding (6, 17) . In a previous study of 118 patients evaluating half-dose versus fulldose alteplase therapy, major bleeding occurred in 3% of half-dose compared with 10% of full-dose treated patients (p = 0.29) (17) . It is possible that the similar rates of major bleeding observed between treatment groups in our study are due to patient selection. Patients with a higher perceived risk of bleeding may have preferentially been given half-dose alteplase therapy as a more conservative strategy. However, we did not observe any preferential use of halfdose alteplase therapy in patients with increased bleeding risk, such as those greater than 65 years old, or those with renal or hepatic dysfunction, cancer, or coagulopathies. It is possible that other unidentified bleeding risk factors were present in the half-dose group; if so, one may conclude that using half-dose therapy in these patients may result in similar bleeding rates to full-dose alteplase therapy. Although it is reasonable to assume that utilizing a lower dose of alteplase will reduce the risk of bleeding in a dose-dependent manner, currently no comparative evidence has demonstrated that lower dose alteplase significantly reduces major bleeding or the frequency of intracranial hemorrhage in patients with acute PE. Therefore, the use of the term "safe" dose thrombolysis to describe half-dose therapy should be avoided. This is especially true since our study found that half-dose alteplase was associated with higher rates of secondary thrombolysis and catheter fragmentation, therapies that carry additional risks.
Several limitations should be considered when interpreting the results of this study due to its observational design. We were not able to determine why a particular thrombolytic treatment strategy was chosen in the study patients or assess utilization of hospital-based treatment protocols. Patient body weight was unavailable in the database, so evaluation of weight-based dosing on effectiveness and safety outcomes was not possible. Vital signs, echocardiographic, and laboratory results are not available within the database, so differentiation of high-risk and intermediate-risk PE was conducted based upon vasopressor usage at the time of alteplase administration. Additionally, this limited our ability to evaluate treatment strategies by the more contemporary definitions of low-, intermediate-, and high-risk PE subgroups. Our analysis of major bleeding is limited to the availability of specific diagnostic codes and the use of rescue pharmacologic therapy, which limits our analysis to only certain types of major bleeding. Additionally, we were unable to measure the occurrence of minor bleeding or long-term outcomes. Hospital costs may be reflective of a variety of patient and hospital factors, and actual differences due to alteplase treatment may not be fully explained by the data. Although rigorous statistical methods were used, including propensity score matching and covariate adjustment, it is possible that residual biases remain.
CONCLUSIONS
Our data suggest that initiating treatment with half-dose alteplase for PE is much less common than utilization of fulldose therapy, but its use appears to be increasing. Mortality between thrombolysis treatment strategies were similar and approximately 46% of patients treated with half-dose therapy did not require further intervention. However, in comparison to full-dose therapy, escalation of care occurs more frequently. Additionally, no clear differences in major bleeding (most notably intracerebral hemorrhage) or adverse events occurred between half-dose and full-dose therapies. Preferably, a prospective clinical trial should be performed to determine the optimum alteplase dose that maximizes benefits and minimizes the risk of bleeding, particularly for patients with intermediate-risk PE.
